Meta-analyses of randomized trials studying the effects of treatments on vascular disease risk
Lead Research Organisation:
University of Oxford
Abstract
For many drugs that influence the risk of major vascular events (heart attacks, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. For several classes of drugs (statins for heart disease and stroke, antiplatelet agents such as aspirin for diabetes, the clot-busting drug alteplase in acute stroke, and angiotensin-receptor blockers in Marfan’s Syndrome) we have established collaborations in which investigators have provided detailed individual patient data from their randomized trials that are addressing a particular clinical question. In each case we aim to generate new combined analyses that provide insights that are not apparent from the individual trials, but which only emerge when the data are combined. These analyses help to identify which patients derive the most benefit (or who are susceptible to harm), and help in developing a better understanding of how each individual treatment works. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.
Technical Summary
For many drugs that influence the risk of major vascular events (myocardial infarction, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. This programme is focused on several ongoing collaborations in which investigators have provided detailed individual patient data from their randomized trials studying the effects of a particular class of drug. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.
Current work is focused on 4 main areas:
(i) The Cholesterol Treatment Trialists’ (CTT) Collaboration aims to test claims of particular side-effects of statins arising from observational studies (for example, an increased risk of cataract, sleep disturbances, memory loss, or depression), concerns about which are inhibiting prescribing of statins in patients at high risk of cardiovascular disease, with potentially adverse effects on public health. We are currently working with the sponsors of 29 large trials that have previously provided data on vascular events, cancer and mortality in order to obtain supplementary datasets on adverse events, which will then be merged with existing data. We plan to conduct meta-analyses of the effects of statins on a wide range of adverse events once data collection is complete.
(ii) In accordance with a published protocol, the Stroke Thrombolysis Trialists’ (STT) Collaboration has already reported analyses of the effects of alteplase on the proportions surviving without disability and the risks of haemorrhagic stroke in 10 trials conducted in acute ischaemic stroke. We now plan supplementary analyses of the existing database, new data collection to permit analyses of CT scan data, and the incorporation of additional data from completed or ongoing randomized trials.
(iii) The Antithrombotic Trialists’ (ATT) Collaboration is planning updated individual patient data analyses of the effects of aspirin on vascular outcomes in low-risk populations with and without diabetes, which will incorporate the results of major ongoing trials, including the Unit’s own ASCEND trial among 15,000 people with diabetes but no known history of vascular disease.
(iv) The Marfan Trialists’ Collaboration (MTC) is preparing to collect individual patient data from 10 randomized trials examining the effects of angiotensin-receptor blockers and of beta-blockers in order to reduce the rate of expansion of the aortic root, which ultimately can lead to fatal aortic rupture.
Current work is focused on 4 main areas:
(i) The Cholesterol Treatment Trialists’ (CTT) Collaboration aims to test claims of particular side-effects of statins arising from observational studies (for example, an increased risk of cataract, sleep disturbances, memory loss, or depression), concerns about which are inhibiting prescribing of statins in patients at high risk of cardiovascular disease, with potentially adverse effects on public health. We are currently working with the sponsors of 29 large trials that have previously provided data on vascular events, cancer and mortality in order to obtain supplementary datasets on adverse events, which will then be merged with existing data. We plan to conduct meta-analyses of the effects of statins on a wide range of adverse events once data collection is complete.
(ii) In accordance with a published protocol, the Stroke Thrombolysis Trialists’ (STT) Collaboration has already reported analyses of the effects of alteplase on the proportions surviving without disability and the risks of haemorrhagic stroke in 10 trials conducted in acute ischaemic stroke. We now plan supplementary analyses of the existing database, new data collection to permit analyses of CT scan data, and the incorporation of additional data from completed or ongoing randomized trials.
(iii) The Antithrombotic Trialists’ (ATT) Collaboration is planning updated individual patient data analyses of the effects of aspirin on vascular outcomes in low-risk populations with and without diabetes, which will incorporate the results of major ongoing trials, including the Unit’s own ASCEND trial among 15,000 people with diabetes but no known history of vascular disease.
(iv) The Marfan Trialists’ Collaboration (MTC) is preparing to collect individual patient data from 10 randomized trials examining the effects of angiotensin-receptor blockers and of beta-blockers in order to reduce the rate of expansion of the aortic root, which ultimately can lead to fatal aortic rupture.
Organisations
- University of Oxford, United Kingdom (Lead Research Organisation)
- University of Edinburgh, United Kingdom (Collaboration)
- VU University Medical Center (Collaboration)
- University of Texas Southwestern Medical Center (Collaboration)
- Russells Hall Hospital (Collaboration)
- Nordic School of Public Health (Collaboration)
- Mayo Clinic (Collaboration)
- Tokai University (Collaboration)
- State University of New York (Collaboration)
- University of Sydney, Australia (Collaboration)
- New England Research Institute (Collaboration)
- Georgetown University, United States (Collaboration)
- Oslo University Hospital (Collaboration)
- University of Dundee, United Kingdom (Collaboration)
- Sahlgrenska University Hospital (Collaboration)
- Florida Atlantic University (Collaboration)
- Rosalind Franklin University of medicine (Collaboration)
- Johns Hopkins Medicine (Collaboration)
- University of Rome I (La Sapienza), Italy (Collaboration)
- AstraZeneca plc (Collaboration)
- University of Cagliari, Italy (Collaboration)
- Stanford University, United States (Collaboration)
- Leiden University Medical Center (Collaboration)
- United States Department of Veterans Affairs (Collaboration)
- Washington University in St. Louis (Collaboration)
- King Fahd Hospital, Saudi Arabia (Collaboration)
- Fred Hutchinson Cancer Research Center (FHCRC) (Collaboration)
- Hamilton Health Sciences (Collaboration)
- University of Texas at San Antonio, United States (Collaboration)
- Auckland City Hospital (Collaboration)
- University of Louisville (Collaboration)
- Erasmus University Medical Center, Netherlands (Collaboration)
- UNLISTED (Collaboration)
- Taipei Veterans General Hospital (Collaboration)
- Pfizer Ltd (Collaboration)
- Firat University (Collaboration)
- Uni of Texas Health Sci Ctr San Antonio (Collaboration)
- Lund University (Collaboration)
- University Hospital, Josef-Schneider-Str 2, Germany (Collaboration)
- George Institute for Global Health (Collaboration)
- King's College London, United Kingdom (Collaboration)
- University College London, United Kingdom (Collaboration)
- Tripler Medical Army Center, US (Collaboration)
- University of Arizona, United States (Collaboration)
- University Hospital Cleveland (Collaboration)
- Vall d'Hebron University Hospital (Collaboration)
- University of Lyon (Collaboration)
- Academic Medical Center (Collaboration)
- Florey Neurosciences Institute Melbourne Australia (Collaboration)
- Massachusetts General Hospital (Collaboration)
- University of Ottawa, Canada (Collaboration)
- Fondazione IRCCS Policlinico San Matteo (Collaboration)
- University of Ghent, Belgium (Collaboration)
- Sheba Medical Centre (Collaboration)
- Sanofi (Collaboration)
- American University of Beirut (Collaboration)
- Bayer (Collaboration)
- Vanderbilt University, United States (Collaboration)
- John Radcliffe Hospital, United Kingdom (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- Italian Auxological Institute (Collaboration)
- Rikshospitalet , Sogsnsavvsveien (Collaboration)
- Grants Admin Office (Collaboration)
- MAM College of Pharmacology (Collaboration)
- University of Zagreb (Collaboration)
- Cleveland Clinic (Collaboration)
- Johns Hopkins University, United States (Collaboration)
- Antwerp University Hospital (Collaboration)
- University of Gothenburg, Sweden (Collaboration)
- Jacksonville Centre for Clinical Research (Collaboration)
- Statistics Collaborative (Collaboration)
- Tisch Hospital (Collaboration)
- Pharma Clinical (Collaboration)
- University College Dublin, Ireland (Collaboration)
- Boehringer Ingelheim, Germany (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- Harvard University (Collaboration)
- Ecological Institute of Caspian Sea (Collaboration)
- ANMCO Research Centre (Collaboration)
- St Mary's Hospital, London (Collaboration)
- University of Toronto (Collaboration)
- University of Wuerzburg, Germany (Collaboration)
- Helsinki University Central Hospital (Collaboration)
- University of Pennsylvania, United States (Collaboration)
- Hospital of Psychiatry and Psychotherapy, Germany (Collaboration)
- Northwestern University (Collaboration)
- University of North Texas (Collaboration)
- University of Utah, United States (Collaboration)
- National Taiwan University, Taiwan, Province of China (Collaboration)
- Mitsukoshi Health & Welfare Foundation (Collaboration)
- Bichat-Claude Bernard Hospital (Collaboration)
- University of Melbourne, Australia (Collaboration)
- Royal London Hospital (Collaboration)
- The University of Iowa, United States (Collaboration)
- Mario Negri Institute for Pharmacological Research (Collaboration)
- Rush University Medical Center, United States (Collaboration)
- Cedars-Sinai Medical Center (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- London Sch of Hygiene and Trop Medicine, United Kingdom (Collaboration)
- Brigham and Women's Hospital (Collaboration)
- University of Glasgow, United Kingdom (Collaboration)
- Merck (Collaboration)
- University of East Anglia, United Kingdom (Collaboration)
- Technical University Dresden, Germany (Collaboration)
- Queen's Medical Centre (Collaboration)
- Pfizer, United States (Collaboration)
- New York University, United States (Collaboration)
- Royal Brompton Hospital (Collaboration)
- University of Alabama at Birmingham, United States (Collaboration)
- Ulleval University Hospital (Collaboration)
- Sasaki Institute (Collaboration)
- Toronto General Hospital (Collaboration)
- Gastrointestinal & Other Cancers Research Group (Collaboration)
- Churchill Hospital (Collaboration)
- Catholic University of the Sacred Heart (Collaboration)
- Tri-Services General Hospital (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- Thrombosis Center of Buenos Aires (Collaboration)
- Ogun State University Teaching Hospital (OSUTH) (Collaboration)
- Seoul National University (Collaboration)
- National Cerebral and Cardiovascular Centre (Collaboration)
- Linkoping University (Collaboration)
- Novartis (Collaboration)
- Hennepin County Medical Center (Collaboration)
- National Heart, Lung, and Blood Institute (NHLBI) (Collaboration)
- Mexican Social Security Insitute (IMSS) (Collaboration)
- BC Children's Hospital (Collaboration)
- University of Maryland, United States (Collaboration)
- University of Zaragoza (Collaboration)
- Schulthess Clinic (Collaboration)
- McMaster University, Canada (Collaboration)
- Uppsala University (Collaboration)
- Monash University, Australia (Collaboration)
- Tufts University (Collaboration)
- Beijing Huilongguan Hospital (Collaboration)
- Wake Forest University, United States (Collaboration)
- University College London Hospital (UCLH) NHS Foundation Trust (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Glasgow Royal Infirmary (Collaboration)
- Boston Children's Hospital (Collaboration)
- University of Chieti Pescara, Italy (Collaboration)
People |
ORCID iD |
| Colin Baigent (Principal Investigator) |
Publications
Armitage J
(2016)
Lessons from the controversy over statins - Authors' reply
in The Lancet
ASCEND Study Collaborative Group
(2018)
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
in The New England journal of medicine
Baigent C
(2017)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.
in Kidney international
Baigent C
(2018)
Should We Increase GFR with Bardoxolone in Alport Syndrome?
in Journal of the American Society of Nephrology : JASN
Cholesterol Treatment Trialists' (CTT) Collaboration
(2016)
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.
in American heart journal
Collins R
(2016)
Interpretation of the evidence for the efficacy and safety of statin therapy.
in Lancet (London, England)
Gross O
(2017)
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Hacke W
(2018)
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
in International journal of stroke : official journal of the International Stroke Society
Haynes R
(2018)
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
in Circulation
Herrington W
(2016)
Are statins useful in patients with advanced chronic kidney disease? - Authors' reply
in The Lancet Diabetes & Endocrinology
| Guideline Title | Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children |
| Description | Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018. |
| Description | Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Acute Inpatient Stroke Care, 6th Edition, Update 2018 |
| Description | Impact of STT paper Effects of alteplase for acute stroke according to criteria defining the EU and US marketing authorizations: Individual-patient-data meta-analysis of randomized trials |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Influenced clinical guidelines |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Brigham and Women's Hospital |
| Department | Division of Cardiovascular Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Catholic University of the Sacred Heart |
| Department | School of Medicine (UCSC) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Florida Atlantic University |
| Department | Charles E. Schmidt College of Science |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Italian Auxological Institute |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Clinical Gerontology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Monash University |
| Department | Department of Epidemiology and Preventive Medicine |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | ANMCO Research Centre |
| Country | Italy |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Auckland City Hospital |
| Country | New Zealand |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Bayer |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Bristol-Myers Squibb |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Churchill Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Erasmus University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Fred Hutchinson Cancer Research Center (FHCRC) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Glasgow Royal Infirmary |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Hamilton Health Sciences |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Harvard University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Hennepin County Medical Center |
| Department | Division of Clinical Epidemiology |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Jacksonville Centre for Clinical Research |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | John Radcliffe Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | King's College London |
| Department | Cardiovascular Division |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Multiple |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Department | Consorzio Mario Negri Sud (CMNS) |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Department | Consorzio Mario Negri Sud (CMNS) |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | McMaster University |
| Department | Population Health Research Institute |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mitsukoshi Health & Welfare Foundation |
| Country | Japan |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | National Heart, Lung, and Blood Institute (NHLBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Nordic School of Public Health |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Oslo University Hospital |
| Department | Department of Cardiology |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Oslo University Hospital |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Pfizer Global R & D |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Pharma Clinical |
| Country | Israel |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Rikshospitalet , Sogsnsavvsveien |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Rosalin Franklin University |
| Department | School of Medicine Rosalin Franklin |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Royal London Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Russells Hall Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sahlgrenska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sahlgrenska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sanofi |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | St Mary's Hospital, London |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | State University of New York |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Tokai University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Ulleval University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | United States Department of Veterans Affairs |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College London Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University Hospital, Josef-Schneider-Str 2, Germany |
| Department | Division of Nephrology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University Hospitals of Cleveland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Dundee |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Glasgow |
| Department | School of Medicine Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Iowa |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of North Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Sydney |
| Department | Sydney Medical School |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas |
| Department | School of Public Health Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas Health Science Center San Antonio, BrainMap Database |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas Southwestern Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Uppsala University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | VU University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Wake Forest University |
| Department | Wake Forest School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | American University of Beirut |
| Department | Epidemiology and Population Health Department |
| Country | Lebanon |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Beijing Huilongguan Hospital |
| Country | China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Cleveland Clinic |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Ecological Institute of Caspian Sea |
| Country | Iran, Islamic Republic of |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Firat University |
| Country | Turkey |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Gastrointestinal & Other Cancers Research Group |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Georgetown University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Hospital of Psychiatry and Psychotherapy, Germany |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Icahn School of Medicine at Mount Sinai |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Johns Hopkins Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Johns Hopkins University |
| Department | Johns Hopkins Bloomberg School of Public Health |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | King Fahd Hospital, Saudi Arabia |
| Country | Saudi Arabia |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Linkoping University |
| Department | University Medical School Linkoping |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | MAM College of Pharmacology |
| Country | India |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Massachusetts General Hospital |
| Department | Cancer Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Mexican Social Security Insitute (IMSS) |
| Country | Mexico |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | New York University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Northwestern University |
| Department | Feinberg School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Ogun State University Teaching Hospital (OSUTH) |
| Country | Nigeria |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Queen's Medical Centre |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Rush University Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Sasaki Institute |
| Country | Japan |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Schulthess Clinic |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Seoul National University |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Statistics Collaborative |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Taipei Veterans General Hospital |
| Country | Taiwan, Province of China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Thrombosis Center of Buenos Aires |
| Country | Argentina |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tisch Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Toronto General Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tri-Services General Hospital |
| Country | Taiwan, Province of China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tripler Medical Army Center, US |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tufts University |
| Department | School of Dental Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Arizona |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Cagliari |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Chieti-Pescara |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Louisville |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Lyon |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Maryland |
| Department | School of Medicine Maryland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Ottawa |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Pennsylvania |
| Department | Institute for Translational Medicine and Therapeutics (ITMAT) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Utah |
| Department | School of Medicine Utah |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Zagreb |
| Country | Croatia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Zaragoza |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Vanderbilt University |
| Department | Vanderbilt Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Cedars-Sinai Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Florey Neurosciences Institute Melbourne Australia |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | George Institute for Global Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Helsinki University Central Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Mayo Clinic |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | National Cerebral and Cardiovascular Centre |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Stanford University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Alabama at Birmingham |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Edinburgh |
| Department | School of Molecular and Clinical Medicine Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Glasgow |
| Department | School of Medicine Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Antwerp University Hospital |
| Department | Center for Medical Genetics |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | BC Children's Hospital |
| Department | Children's Heart Centre |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Bichat-Claude Bernard Hospital |
| Department | French National Reference Centre for Marfan Syndrome |
| Country | France |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Boston Children's Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Fondazione IRCCS Policlinico San Matteo |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | National Heart, Lung, and Blood Institute (NHLBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | National Taiwan University |
| Department | Department of Pediatrics |
| Country | Taiwan, Province of China |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | New England Research Institutes Watertown |
| Country | United States |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Royal Brompton Hospital |
| Department | Clinical Trials and Evaluation Unit |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University College London |
| Department | Institute of Cardiovascular Science |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University of East Anglia |
| Department | Faculty of Medicine and Health Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University of Ghent |
| Department | Centre for Medical Genetics |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Vall d'Hebron University Hospital |
| Department | Department of Cardiology |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group (re. process of writing a new curriculum for pharmaceutical medicine specialty training). This curriculum will include a set of specialty-specific Capabilities in Practice, together with the GMC's Generic Professional Capabilities. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Freeland School visit |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | • Interactive game aimed at children to explain what data is and its different types hosted by the VOG Research Team (note : this is being developed further by them going to Freeland Primary School in March 2019 for a full day to deliver this game to all year groups). |
| Year(s) Of Engagement Activity | 2019 |
| Description | NDPH participant panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation of Cholesterol Treatment Trialists' Collaboration (CTT) and Marfan Treatment Trialists' Collaboration (MTT) to the Nuffield Department of Population Health Participant Panel |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.ctsu.ox.ac.uk/research/participant-panel |
| Description | Oxford Open Doors 2018 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Open day for the general public, with talks and interactive activities. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Science Media Centre Expert Panel |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Press conference to share results of the effects of statins on the elderly: • In relation to CTT elderly paper (see: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext); attended by Colin Baigent and Boby Mihaylova; see: https://www.sciencemediacentre.org/expert-reaction-to-meta-analysis-looking-at-statins-and-cardiovascular-events-in-all-ages/. |
| Year(s) Of Engagement Activity | 2019 |